B3GAT1 and COVID-19: Interestingly, we observed a significant surge in the percentage of CD57+CD8+ T cells among COVID-19 patients at inclusion compared to healthy controls, which increased further by the 6 week time point and was sustained up until 6-7 months (Figure 5B).